Trial Profile

A phase 1 trial of GENA-104

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 20 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GENA 104 (Primary)
Indications Solid tumours
Focus Adverse reactions

Most Recent Events

20 Feb 2025 New trial record
11 Feb 2025 According to an Ellipses Pharma media release, Phase 1 IND was approved by the South Korean Ministry of Food and Drug Safety in January 2024 and company expects to initiate a Phase 1 clinical trial in South Korea during 2025 with expansion of involvement to the US and Europe following the relevant regulatory approvals.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com